Nicholas Investment Partners LP Sells 9,263 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Nicholas Investment Partners LP sharply reduced its Intuitive Surgical stake in the fourth quarter, selling 9,263 shares and cutting its position by 87.4% to 1,341 shares worth about $759,000.
• Intuitive Surgical reported stronger-than-expected quarterly results, with EPS of $2.50 versus $2.08 estimated and revenue of $2.77 billion, up 23% year over year.
• Analyst sentiment remains mixed but generally positive: the stock carries a “Moderate Buy” consensus, though several firms lowered price targets and Deutsche Bank issued a sell rating with a $366 target.

Nicholas Investment Partners LP cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 87.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,341 shares of the medical equipment provider's stock after selling 9,263 shares during the period. Nicholas Investment Partners LP's holdings in Intuitive Surgical were worth $759,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ISRG. Holos Integrated Wealth LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at about $25,000. Newbridge Financial Services Group Inc. grew its position in shares of Intuitive Surgical by 300.0% during the 4th quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider's stock worth $25,000 after buying an additional 33 shares during the period. Olistico Wealth LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. Caitlin John LLC bought a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $30,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $31,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $411.06 on Monday. The stock has a market cap of $145.58 billion, a price-to-earnings ratio of 49.83, a PEG ratio of 3.28 and a beta of 1.46. The business has a 50 day simple moving average of $442.88 and a 200 day simple moving average of $495.68. Intuitive Surgical, Inc. has a 52-week low of $396.68 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating analysts' consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The business's revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 earnings per share. On average, analysts predict that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Evercore reduced their price objective on shares of Intuitive Surgical from $550.00 to $480.00 and set a "neutral" rating on the stock in a research note on Monday, April 6th. Raymond James Financial lowered their target price on shares of Intuitive Surgical from $615.00 to $577.00 and set an "outperform" rating for the company in a research note on Wednesday, April 22nd. Mizuho set a $525.00 price target on shares of Intuitive Surgical and gave the stock a "neutral" rating in a research report on Monday, April 13th. UBS Group reduced their price target on shares of Intuitive Surgical from $570.00 to $550.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Intuitive Surgical from $440.00 to $366.00 and set a "sell" rating for the company in a report on Tuesday, June 2nd. Nineteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and an average target price of $571.28.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the completion of the transaction, the senior vice president owned 6,463 shares in the company, valued at approximately $2,718,014.65. This represents a 46.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares in the company, valued at $2,426,080.80. This represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,169 shares of company stock worth $3,059,135 over the last ninety days. Company insiders own 0.60% of the company's stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analyst coverage remains broadly constructive, with brokerage sentiment still at a “Moderate Buy” and recent EPS estimate increases signaling confidence in Intuitive Surgical’s growth outlook.
• Positive Sentiment: Recent commentary highlights that the company’s scale, cost discipline, and adoption of the da Vinci 5 platform could help protect margins even if tariffs and input costs remain a concern.
• Neutral Sentiment: Investor attention has increased around ISRG, which can support trading activity, but this appears more like watchlist interest than a fresh business catalyst.
• Neutral Sentiment: BofA trimmed its price target slightly to $515 from $520, which still implies upside but signals a bit less optimism than before. Article: BofA adjusts price target on Intuitive Surgical to $515 from $520
• Neutral Sentiment: Two executives sold shares under pre-arranged 10b5-1 plans, including EVP Gary Loeb and EVP Mark Brosius. The sales were relatively small and routine, so they are unlikely to be a major fundamental concern.
• Negative Sentiment: One recent research note was notably bearish, with Deutsche Bank cutting its target to $366 and maintaining a sell rating, reinforcing concerns that valuation may still be too rich despite the company’s strong operating performance.
• Negative Sentiment: Seeking Alpha published a view calling Intuitive Surgical an “excellent business, unattractive stock,” reflecting ongoing investor caution around the valuation. Article: Intuitive Surgical: Excellent Business, Unattractive Stock

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. Intuitive's business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.